Phase 2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 (trastuzumab imbotolimod) plus /- pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab deruxtecan (T-DXd) Meeting Abstract
| Authors: | Pegram, M. D.; Calfa, C.; Chen, C.; Cortés Salgado, A.; Heeke, A. L.; Kang, I.; Pistilli, B.; Pohlmann, P. R.; Rugo, H. S.; Saura, C.; Vicier, C.; Pearson, C.; Mangeshkar, M.; Yu, T.; Alonso, M. N.; Colburn, D. E.; Perez, E. A.; Drago, J. Z. |
| Abstract Title: | Phase 2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 (trastuzumab imbotolimod) plus /- pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab deruxtecan (T-DXd) |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557406026 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.TPS1121 |
| Notes: | Meeting Abstract: TPS1121 -- Source: Wos |
